Immunocore
Immunocore:
Developer of the world’s first approved TCR-therapeutic KIMMTRAK and pioneering a new class of therapeutics to deliver transformative medicines to patients in cancer, infection, and autoimmune. KIMMTRAK generated net revenues of $34M in 2Q22 for patients with metastatic uveal melanoma. Durable clinical activity was presented (ESMO 2022) for PRAME in multiple solid tumors and have initiated four expansion arms.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Marketed, Phase III, Phase l or ll
Disease Space
Anti-infectives, Antivirals, Immuno-Oncology, Immunotherapy, Infectious Disease, Oncology, Rare Disease
Finance
Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Antibodies, Cell Therapy, Platform Technology
Website:
Profiles:
Address:
Abingdon, Oxfordshire
United Kingdom
United Kingdom
More info:
My account:
Company Participants at Immunocore PRAME Investor & Analyst Event at ESMO 2022
- Bahija Jallal, CEO
Lead Programs
Kimmtrak
| Indication | Phase |
|---|---|
| metastatic uveal Melanoma | Marketed |
| Advanced Melanoma | 2/3 |
Top 10 Holders of Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| RTW Investments LP | 11.75 | 5,649,943 | 317.70 | 13F | 3/31/23 |
| Wellington Management Co. LLP | 7.02 | 3,375,309 | 189.79 | 13F | 3/31/23 |
| Rock Springs Capital Management LP | 6.24 | 3,001,662 | 168.78 | 13F | 3/31/23 |
| Baker Bros. Advisors LP | 5.24 | 2,520,731 | 141.74 | 13F | 3/31/23 |
| Fidelity Management & Research Co. LLC | 3.90 | 1,873,557 | 105.35 | 13F | 3/31/23 |
| T. Rowe Price Associates, Inc. (Investment Management) | 2.88 | 1,383,440 | 77.79 | 13F | 3/31/23 |
| Paradigm BioCapital Advisors LP | 2.34 | 1,126,256 | 63.33 | 13F | 3/31/23 |
| General Atlantic LLC | 1.98 | 950,000 | 53.42 | 13F | 3/31/23 |
| Pictet Asset Management SA | 1.85 | 888,951 | 49.99 | 13F | 3/31/23 |
| Avidity Partners Management LP | 1.60 | 769,800 | 43.29 | 13F | 3/31/23 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2023 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.